News brief
On 2026-07-14, according to Xiniu Data, iRegene completed equity financing for an undisclosed amount. Investors were Suzhou Xingzexingyongxinxing Medical Industrial Investment Fund Management Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年7月14日，据烯牛数据报道，睿健医药完成股权投资融资，金额未披露。投资方为苏州杏泽兴涌新兴医疗产业投资基金管理合伙企业（有限合伙）。该公司为化学诱导细胞治疗药物研发商。